Zydus Cadila receives EIR for Moraiya manufacturing facility
Mumbai: Pharma Major, Zydus Cadila's formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) signifying the successful closure of the audit.
The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations.
Post the audit, the plant has received several product approvals,including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.
AhmedabadauditEIREstablishment Inspection ReportMesalamine Delayed- Release TabletsMoraiya facilityproduct approvalreceiveUSUSFDAZydus Cadila
Source : UNINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd